Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice - Wikidata - wikimedia - TriplyDB

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

http://www.wikidata.org/entity/Q30473360

about

Dysregulation and restoration of translational homeostasis in fragile X syndrome Emerging pharmacologic treatment options for fragile X syndrome Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.The pathophysiology of fragile X (and what it teaches us about synapses)Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss.Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspring From FMRP function to potential therapies for fragile X syndrome.Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.Soy-based diet exacerbates seizures in mouse models of neurological disease Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease.Fluorescent labeling of dendritic spines in cell cultures with the carbocyanine dye "DiI".A hypothesis regarding the molecular mechanism underlying dietary soy-induced effects on seizure propensity Abnormal intracellular accumulation and extracellular Aβ deposition in idiopathic and Dup15q11.2-q13 autism spectrum disorders Increasing our understanding of human cognition through the study of Fragile X Syndrome.Fragile X mental retardation protein expression in Alzheimer's disease Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.Neuronal nucleus and cytoplasm volume deficit in children with autism and volume increase in adolescents and adults.Fragile X mental retardation protein: from autism to neurodegenerative disease.Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System.The regulation of AβPP expression by RNA-binding proteins Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex.Persistent astrocyte activation in the fragile X mouse cerebellum Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase,Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model.Outcome measures for clinical trials in fragile X syndrome.APP Causes Hyperexcitability in Fragile X Mice.Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models.Commentary: Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis.Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aβ Antibody and by mGluR5 Blockade.What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.A common STEP in the synaptic pathology of diverse neuropsychiatric disorders.Fragile X mental retardation protein and synaptic plasticity Progress toward treatments for synaptic defects in autism.

P2860

Q26782616-3B2CE6C7-D4C5-4137-BA0A-902605497543 Q26829152-CE53E4F4-21BC-4216-B98E-9063D45F5F76 Q26866506-DDC5D9FA-13A4-4CB7-8324-9A368D286997 Q27010675-E3758914-939C-4004-8588-F9394B3258DD Q27023257-4ABA4F03-A299-4480-AFAD-8A3AB04E20B8 Q27303472-EFA4E62B-5941-4FEE-8A60-39B7E6952622 Q27337360-36C3962C-0516-423E-B5DE-DDF6858BCCCA Q28261563-DC2E09D5-EC5E-4437-8DDF-1A58B3270950 Q28941206-571ECDD5-8CEF-406E-B68F-38D9A481CF6B Q30410502-A3A69ED6-E6BE-447B-A2A1-308AACDC4641 Q30418368-B631EF2B-574F-452D-8EF5-204E4828BB59 Q30445118-43382359-E1C5-417F-885C-D1539ED2859E Q30580280-CF1C8706-9AC1-4DFE-ADD6-2FCBEDFE12A8 Q33620157-14C957DE-FB99-4687-83B0-A37E2F81614F Q34125778-BCA6B5F8-0BBC-4105-B04A-668232A50247 Q34261556-61E87CF6-AB42-4688-B5FA-B1866970908E Q34435526-0084B38B-15EA-41E4-9239-48B2D84C6898 Q34521866-36A54F99-4D8E-494E-B5C4-15D52044FC48 Q34620558-374791E6-2A76-42A2-9F4D-0A9A640AEFAC Q34871401-7438376B-63E9-4B96-A555-C58D4FB6EDC1 Q34998124-A4FD626F-1D66-4C6E-B128-1022B9B7B731 Q35077291-99532846-09AC-454B-BABF-BBD795230F9D Q35980653-45EEE490-6836-473E-9461-1AD5012B180B Q36110142-187EFC9A-FA07-4CFB-B066-9A6069F9A68B Q36161795-277E5515-5BFB-433D-A80E-33DD82D60A14 Q36186534-74C87B1A-6EB4-4967-9EA0-5C7A3EB90D9C Q36498006-E0674798-B9BD-4716-9B58-73BBDE07E8D5 Q36925690-70451669-7C9C-4F2B-B1F2-81A532EF77BA Q36985727-8F82DB2A-F7D7-46F2-B5AB-9CB6E301EAAD Q37054398-2917AFBF-19FF-4FD8-AF98-D4AF2F64FBBF Q37148507-35E2AF24-658E-4D68-9F1E-9BA4850B37FE Q37199656-F70BDB56-B2C1-4DB0-BBBC-2BF8748E5FAC Q37504141-6468513D-B822-4D5D-A165-0E06B2A000DE Q37564195-AB085168-89C9-4653-B822-40D10589E0B8 Q37627065-E9EFBA1F-D71F-4587-BBD7-0066E99E474B Q37719047-6816C384-5EC5-4034-9407-DA7469EA6EFA Q38038399-46A965E9-08FD-4A23-A563-AB6D29D9A07A Q38067390-4F29AD3E-38B4-4DF3-B018-90607BCC0FBE Q38097197-4E4E10C5-554F-4553-BFE1-C1A05A9D985B Q38112617-8D2C33BF-26A3-494D-BC9A-4CF9F823D7B7

P2860

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

http://www.wikidata.org/entity/Q30473360

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

@ast

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

@en

type

label

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

@ast

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

@en

prefLabel

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

@ast

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

@en

P1433

Q30473360-654E463A-BEE3-4239-B947-9082F5CA2235

P1476

Q30473360-F777093E-00BB-4FE1-B5F7-45D232AA8225

P2093

Q30473360-09B25CE3-C2DF-4EF7-BB1E-A0EC5C8E2750

Q30473360-0C6A5E40-B4C6-4786-8464-BDCB2E9119CB

Q30473360-34F580DE-E1F3-4923-B489-9CAB29172133

Q30473360-36DAB502-61F2-4616-A6EB-74CCBF1025C6

Q30473360-4DEB71C8-E3BC-4231-AC8D-D136916E669C

Q30473360-7374377B-34A1-440C-A4ED-B2185C0239AF

Q30473360-7A69D264-7FB2-4E85-A3F6-9B0FF8C25828

Q30473360-7FB071F3-CC2F-4862-9E88-8D35F95181E2

Q30473360-83E31745-D916-4299-B5FE-0C7E5DE128A7

Q30473360-88EF01E4-E252-426B-BF1E-73067176B835

P2860

Q30473360-01422BB6-BCD6-4128-B9F5-670120BF7F01

Q30473360-032F6A63-5B77-4414-B4D7-9BCF109534F7

Q30473360-084DCB1B-A80A-479E-A8F9-4ECCC0EFFEF9

Q30473360-090E2854-08C1-4B16-B313-C12ABF75E781

Q30473360-0BFC59F0-29A2-4614-BD32-1B2727C4A865

Q30473360-0C15AF7A-94C7-4380-820D-8B3D0C8E70D0

Q30473360-0CE8A9BE-72D7-4ADA-9D9B-575F995B3532

Q30473360-12DACFED-8CA5-43A1-AD05-8B83336DF3C9

Q30473360-17EB32B8-0ADF-4F7E-9C5A-FDF22FBC99CD

Q30473360-20A4B2BE-A515-44BB-B0B3-C5E0AC7D5AC4

P304

Q30473360-8D4A993B-31EC-42C7-B86D-E3007ABD87F1

P31

Q30473360-B2202112-3D42-4B94-9D8E-033631A5F424

P356

Q30473360-74A0C846-167D-4ADC-B526-7D21386111D0

P407

Q30473360-6F59B6BB-8018-4122-930A-7592FB60D6A7

P433

Q30473360-6B70830A-5FFB-4B2D-80B7-48E0D3D35F8C

P478

Q30473360-52938E1F-DCC5-4F45-A076-19EE04CE5977

P50

Q30473360-08AE9609-97A2-433A-B653-4BB1BE93D2E0

Q30473360-934C5E78-FE8D-4A50-BF90-22FFD6BFAA8F

P577

Q30473360-9FE588D1-30CC-4A20-A25D-9553CE01BB89

P5875

Q30473360-C3929558-7100-40A2-8874-E5780E75378C

P698

Q30473360-9AAA06C4-0C12-471C-98FE-C990E8ADC52C

P932

Q30473360-261B2B8C-951B-4542-BF32-4B9CCCCEBC66

P356

JOURNAL.PONE.0026549

P1433

P1476

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice

@en

P2093

Brian C Ray

http://www.w3.org/2001/XMLSchema#string

Cara J Westmark

http://www.w3.org/2001/XMLSchema#string

Crystal M Hervey

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Berry-Kravis

http://www.w3.org/2001/XMLSchema#string

James S Malter

http://www.w3.org/2001/XMLSchema#string

Kelsey M Stein

http://www.w3.org/2001/XMLSchema#string

Levi A Stodola

http://www.w3.org/2001/XMLSchema#string

M Shahriar Salamat

http://www.w3.org/2001/XMLSchema#string

Michael Tranfaglia

http://www.w3.org/2001/XMLSchema#string

Pamela R Westmark

http://www.w3.org/2001/XMLSchema#string

P2860

Correction of fragile X syndrome in mice.

Altered synaptic plasticity in a mouse model of fragile X mental retardation

Amyloid plaque core protein in Alzheimer disease and Down syndrome

Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake

Evidence that fragile X mental retardation protein is a negative regulator of translation

Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Dendritic anomalies in disorders associated with mental retardation

P304

e26549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0026549

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth J O'Riordan

P577

2011-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51761106

http://www.w3.org/2001/XMLSchema#string

P698

22046307

http://www.w3.org/2001/XMLSchema#string

P932

3202540

http://www.w3.org/2001/XMLSchema#string